Show
Sort by
-
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis
-
Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy
-
Differential expression and response to anti-TNF alpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis
-
Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis
-
IgM anti-dsDNA antibodies are the main anti-nuclear reactivity induced by infliximab but not etanercept treatment: biological and clinical implications
-
Mannose-binding lectin polymorphisms in rheumatoid arthritis and the associations with radiological progression rate and serological markers
-
Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase are pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity
-
Increased systemic and local expression of toll-like receptor 2 and 4 in spondyloarthropathy is downmodulated by tumour necrosis factor alpha blockade
-
Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity : biologic and clinical implications in autoimmune arthritis
-
Impact of natural changes in disease activity on synovial histopathology in rheumatoid arthritis